TW202333730A - 治療由非鴉片類藥物調節的呼吸抑制之方法 - Google Patents

治療由非鴉片類藥物調節的呼吸抑制之方法 Download PDF

Info

Publication number
TW202333730A
TW202333730A TW111141904A TW111141904A TW202333730A TW 202333730 A TW202333730 A TW 202333730A TW 111141904 A TW111141904 A TW 111141904A TW 111141904 A TW111141904 A TW 111141904A TW 202333730 A TW202333730 A TW 202333730A
Authority
TW
Taiwan
Prior art keywords
substituted
hours
compound
hour
alkyl
Prior art date
Application number
TW111141904A
Other languages
English (en)
Chinese (zh)
Inventor
喬瑟夫 伯格利兹
湯瑪士 米勒
艾爾弗瑞多 史威克威
Original Assignee
美商安納萊爾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安納萊爾治療公司 filed Critical 美商安納萊爾治療公司
Publication of TW202333730A publication Critical patent/TW202333730A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111141904A 2021-11-02 2022-11-02 治療由非鴉片類藥物調節的呼吸抑制之方法 TW202333730A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163274722P 2021-11-02 2021-11-02
US63/274,722 2021-11-02

Publications (1)

Publication Number Publication Date
TW202333730A true TW202333730A (zh) 2023-09-01

Family

ID=86147248

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111141904A TW202333730A (zh) 2021-11-02 2022-11-02 治療由非鴉片類藥物調節的呼吸抑制之方法

Country Status (10)

Country Link
US (2) US12138267B2 (https=)
EP (1) EP4426308A4 (https=)
JP (1) JP2024540198A (https=)
KR (1) KR20240101622A (https=)
CN (1) CN118488840A (https=)
AU (1) AU2022380482A1 (https=)
CA (1) CA3236586A1 (https=)
MX (1) MX2024005389A (https=)
TW (1) TW202333730A (https=)
WO (1) WO2023081185A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
AU2011322147A1 (en) * 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2016007729A1 (en) 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
EP3833346A4 (en) 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use

Also Published As

Publication number Publication date
AU2022380482A1 (en) 2024-05-16
JP2024540198A (ja) 2024-10-31
US20250032496A1 (en) 2025-01-30
EP4426308A1 (en) 2024-09-11
CA3236586A1 (en) 2023-05-11
US20230140606A1 (en) 2023-05-04
EP4426308A4 (en) 2025-09-03
MX2024005389A (es) 2024-07-09
US12138267B2 (en) 2024-11-12
WO2023081185A1 (en) 2023-05-11
CN118488840A (zh) 2024-08-13
KR20240101622A (ko) 2024-07-02

Similar Documents

Publication Publication Date Title
US12150461B2 (en) Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
TW202345837A (zh) 呼吸道刺激劑鼻用調配物
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
US20250114370A1 (en) Methods and compositions for treating drug overdose
JP2005314403A (ja) 新規美白用組成物
TW202333732A (zh) 呼吸道刺激劑之非經腸調配物
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
WO2022234336A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
TW202529771A (zh) 用於治療藥物過量的方法及組合物
JP2008110967A (ja) セトラキサートを含有する美白剤
JP6668039B2 (ja) メラニン産生抑制剤